Edition:
United States

H Lundbeck A/S (HLUKF.PK)

HLUKF.PK on OTC Markets Group

53.00USD
25 May 2017
Change (% chg)

$0.03 (+0.06%)
Prev Close
$52.97
Open
$53.00
Day's High
$53.00
Day's Low
$53.00
Volume
200
Avg. Vol
369
52-wk High
$53.00
52-wk Low
$32.00

Select another date:

Wed, May 10 2017

UPDATE 1-Lundbeck raises earnings guidance for the fourth time in 12 months

May 10 Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday.

BRIEF-Lundbeck Q1 EBIT at DKK 1.01 Billion, above expectations

* 2017 GUIDANCE RAISED BASED ON STRONG REVENUE GROWTH AND IMPROVED PROFITABILITY

BRIEF-Lundbeck enters a conditional agreement to sell part of its headquarters

* LUNDBECK ENTERS A CONDITIONAL AGREEMENT AND DIVESTS PART OF ITS HEADQUARTERS IN COPENHAGEN AND EXPECTS TO RAISE ITS FINANCIAL GUIDANCE BY DKK 200 MILLION

BRIEF-Otsuka and Lundbeck announce top-line results from two phase III clinical trials

* OTSUKA AND LUNDBECK ANNOUNCE IMPROVEMENT OF AGITATION SYMPTOMS RELATED TO ALZHEIMER’S-TYPE DEMENTIA FOLLOWING TREATMENT WITH BREXPIPRAZOLE RELATIVE TO PLACEBO

BRIEF-Health Canada approves Otsuka and Lundbeck's REXULTI as a treatment for schizophrenia in adults

* Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults

Lundbeck gives up on Alzheimer's drug, rival to Axovant pill

Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.

Lundbeck gives up on Alzheimer's drug, rival to Axovant pill

Feb 8 Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.

BRIEF-Lundbeck CEO says not concerned about Trump policies

* Not concerned about the policies of U.S. President Donald Trump.

BRIEF-Lundbeck Q4 EBIT DKK 751 mln, above expectations

* Lundbeck continues to show solid revenue growth and strong improvement in profitability

Lundbeck bets on shark antibodies for new brain drugs

LONDON Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer's and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix.

Select another date:

More From Around the Web